Áttétes emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Szűrhetsz célpontra, országra, vagy csak az EU-13 (Horizon Europe felzárkózó) országok intézményeire.

• Minden célpont
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• PARP 7
• BRCA2 2
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

Az EU-13 szűrő, nem rangsor: csak szűkíti a listát.

30+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· UNICANCER· Frissítve: 2026. okt. 14.

  “poor accrual”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

  NCT03439046· Novartis Pharmaceuticals· Frissítve: 2026. júl. 10.

  “Novartis terminated the trial early because the collected data were sufficient to perform the analysis stated for the primary endpoint.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

  NCT04967248· Novartis Pharmaceuticals· Frissítve: 2025. dec. 4.

  “Low recruitment”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Eli Lilly and Company· Forrás

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Hoffmann-La Roche· Forrás

• To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

  NCT07368998· Hoffmann-La Roche· Forrás

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Hoffmann-La Roche· Forrás

• A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

  NCT07748208· Hoffmann-La Roche· Forrás

• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Hoffmann-La Roche· Forrás

• A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

  NCT06764186· AstraZeneca· Forrás

• Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

  NCT05038735· Novartis Pharmaceuticals· Forrás

• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

  NCT04524000· Novartis Pharmaceuticals· Forrás

• Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

  NCT07679269· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 21
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 63
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 70
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• Impact of Transfer Learning and Model Capacity on Patch-Level Metastasis Detection Across Training Data Regimes.

  Stud Health Technol Inform, 2026. szept.

• A multimodal cross-temporal fusion system for complementary evaluation of neoadjuvant chemotherapy in breast cancer.

  Eur J Radiol, 2026. szept.

• Deep-learning-enabled multi-omics analyses for prediction of future metastasis in cancer.

  Nat Commun, 2026. aug.

• Integrating MRI radiomics and deep learning for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study.

  BMC Med Imaging, 2026. júl.

• A Multimodal Multitask Deep Learning Model Based on Ultrasound RF Signals for Joint Assessment of Breast Masses and Axillary Lymph Nodes Status.

  Ultrasound Med Biol, 2026. júl.

• Establishing a Multimodal Model for Predicting Lymphovascular Invasion in Breast Cancer Using Deep Transfer Learning Based on Ultrasound and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

  Oncol Res Treat, 2026. júl.

• An intelligent MRI-based all-in-one diagnostic strategy for axillary lymph node status in breast cancer.

  Nat Commun, 2026. jún.

• Assessing the performance of deep learning and hand-crafted radiomics models using MRI and ultrasound in predicting axillary lymph node status in breast cancer: a systematic review and meta-analysis.

  Eur Radiol, 2026. jún.

• Deep learning model for noninvasive prediction of Ki-67 expression and prognostic stratification in breast cancer: a multicenter retrospective study.

  Eur Radiol, 2026. máj.

• Accuracy of Deep Learning for Detecting Axillary Lymph Node Metastasis in Breast Cancer: Systematic Review and Meta-Analysis.

  J Med Internet Res, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.